Semi-selective immunoadsorption treatment in myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Biomedical Engineering

Background:

• Myasthenia gravis (MG) is a severe autoimmune neuromuscular disease.
• Current treatments for generalized MG have limitations.
• Novel therapeutic approaches are needed to manage MG effectively.

Purpose of the Study:

• To evaluate the safety and effectiveness of semi-selective plasma perfusion (PP) using the IM-T350 column for severe generalized MG.
• To establish a treatment protocol for PP in MG patients.
• To assess the impact of PP on both autoimmune and genetic forms of MG.

Main Methods:

• Treatment of severe generalized MG patients with plasma perfusion (PP) on an IM-T350 column.
• Implementation of a specific treatment protocol: 6 PP sessions per cycle, 3-7 days between sessions, 1.2 L plasma treated per session, and one adsorbent column per cycle.
• Monitoring of efficiency and undesired effects of the IM-T350 adsorbent material.

Main Results:

• Plasma perfusion (PP) demonstrated good clinical results in patients with autoimmune generalized myasthenia gravis (MG).
• No improvement was observed in patients with genetic MG following PP treatment.
• The study successfully verified the safety and effectiveness of the PP methodology with the IM-T350 column.

Conclusions:

• Semi-selective plasma perfusion (PP) with the IM-T350 column is a safe and effective treatment for autoimmune generalized myasthenia gravis (MG).
• The established treatment protocol provides a viable option for managing severe autoimmune MG.
• PP is not effective for genetic forms of MG, highlighting the need for condition-specific therapies.